Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study

The aim of this study was to understand current trends in trastuzumab use in China as a neoadjuvant/adjuvant therapy for human epidermal growth factor receptor-2 positive (HER2+) breast cancer and identify factors influencing trastuzumab use. This was a retrospective, multicenter, cross-sectional st...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Junjie, Shao, Zhimin, Xu, Binghe, Jiang, Zefei, Cui, Shude, Zhang, Jin, Liao, Ning, Jiang, Jun, Wang, Yongsheng, Ouyang, Quchang, Ying, Ziwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393039/
https://www.ncbi.nlm.nih.gov/pubmed/29794725
http://dx.doi.org/10.1097/MD.0000000000010350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393039/
https://www.ncbi.nlm.nih.gov/pubmed/29794725
http://dx.doi.org/10.1097/MD.0000000000010350

Ejemplares similares